Long-term outcome of patients with p22\textsubscript{phox}-deficient chronic granulomatous disease on Jeju Island, Korea

Hyun Sik Kang, MD, Geol Hwang, MD, Kyung-Sue Shin, MD
Department of Pediatrics, Jeju National University School of Medicine, Jeju, Korea

Purpose: This study investigated the long-term clinical outcomes of patients with p22\textsubscript{phox}-deficient chronic granulomatous disease (CGD) on Jeju Island and retrospectively evaluated the effects of interferon-gamma (IFN-\(\gamma\)) prophylaxis.

Methods: The medical records of 15 patients with CGD were retrospectively reviewed. The efficacy of IFN-\(\gamma\) prophylaxis was evaluated by comparing the frequency of severe infections before and after starting continuous prophylaxis with IFN-\(\gamma\).

Results: At the time of the analysis, 14 patients were alive, with a median age of 14.3 years. The diagnosis of CGD was made at a median age of 2.4 years, and the median age at onset of severe infection was 0.3 years. Thirteen of the 15 patients had their first severe infection within the first year of life. The overall incidence of severe infection was 1.36 infections per patient-year; pneumonia, suppurative lymphadenitis, and skin and subcutaneous abscesses were the most common infections. Aspergillus species were the most frequently isolated microorganisms, present in 15.8% of isolates. IFN-\(\gamma\) did not significantly change the rate of severe infection. The survival rate for patients after 2 years of age was 93%; there was a prolonged survival plateau beyond the age of 2.

Conclusion: Compared with cases of X-linked CGD reported in other studies, patients with CGD on Jeju Island did not show obviously different clinical manifestations, but they had a significantly higher survival rate. Further studies with a substantially longer period of observation, and with more patients under intensive surveillance are necessary to elucidate the prophylactic efficiency of IFN-\(\gamma\).

Key words: Chronic granulomatous disease; Interferon-gamma; Human CYBA protein

Introduction

Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency resulting from defects in any one of the subunits of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase\textsuperscript{1}. The NADPH oxidase complex is composed of five major subunits. Two of these, gp91\textsubscript{phox} (\textit{phox} for phagocytic oxidase) and p22\textsubscript{phox}, are membrane-bound components encoded by the \textit{CYBB} and \textit{CYBA} genes, respectively. The remaining three components include p47\textsubscript{phox}, p67\textsubscript{phox}, and p40\textsubscript{phox}, encoded by the corresponding genes, neutrophil cytosolic factor 1 (\textit{NCF1}), \textit{NCF2}, and \textit{NCF4}\textsuperscript{2}. The NADPH oxidase complex catalyzes the reaction of molecular oxygen to superoxide and related reactive oxygen intermediates (ROIs). Therefore, the functional activity of NADPH oxidase is significantly diminished or completely absent in patients with CGD, resulting in very low or no production of superoxide derivatives, which are important in killing invading microorganisms\textsuperscript{3,4}. The X-linked form of CGD is caused by \textit{CYBB} mutations, and accounts for about 70% of cases. The autosomal recessive (AR) forms are caused by mutations in...
**Materials and methods**

**1. Patients**

The medical records of Jeju National University Hospital from 2001–2012 were reviewed, and 18 patients with a diagnosis of CGD were identified. Diagnosis of CGD was initially based on normal granulocyte function tests, evaluated by a nitroblue tetrazolium test or a dihydrorhodamine-1,2,3 flow cytometry, and confirmed by Western blot analyses and mutation analysis. Because 3 patients had no available continuous follow-up data, 15 patients (6 males, 9 females) who had been seen regularly at the hospital were included in this study. This study was approved by the Institutional Review Board of Jeju National University Hospital (2013-10-002).

**2. Clinical manifestations**

Clinical presentations were reviewed retrospectively from the medical records of 15 patients with CGD. All severe infections were described according to the site of infection and the infectious agents that were isolated from blood, urine, stool, sputum or nasal aspirate, or aspirates of wounds or abscesses. A severe infection was defined as an episode of infection requiring hospitalization and intravenous antimicrobials or surgical treatment. To provide more accurate comparisons when follow–up time differed among groups, severe infections were presented as incidence per patient-year. Patient-years were calculated by adding all of the years that patients were followed in this study and multiplying by the total number of patients.

Chronic conditions, such as hepatosplenomegaly, being underweight or of short stature, anemia of chronic disease, and elevated liver enzymes, were also described. Hepatosplenomegaly was detected by physical examination or surveillance abdominal ultrasound. Being underweight or of short stature was defined as a condition in which the weight or height, respectively, of an individual was more than 3 percentile below the corresponding mean weight or height for a given age and sex. Anemia of chronic disease was regarded as anemia unresponsive to iron therapy, reduced levels of serum iron, serum transferrin, and total iron-binding capacity, or an increased level of serum ferritin.

**3. The efficacy of IFN-γ prophylaxis**

Patients with a body surface area of >0.5 m² received IFN-γ at a dose of 50 µg, whereas those with a body surface area of <0.5 m² received a dose of 1.5 µg/kg. IFN-γ was administered subcutaneously three times weekly. The efficacy of IFN-γ prophylaxis was evaluated by comparing the frequency of severe infections before and after starting continuous prophylaxis with IFN-γ.

**4. Statistical analysis**

The occurrence of the first severe infection and survival rates were analyzed by the Kaplan–Meier method. The Mann–Whitney U test was used to compare differences between the group receiving prophylaxis with IFN-γ and the group without IFN-γ prophylaxis, whereas the Wilcoxon signed–rank test were used to compare the frequency of severe infections before and after prophylaxis with IFN-γ. Statistical processing was carried out with IBM SPSS Statistics 20.0 (IBM Co., Armonk, NY, USA). P values <0.05 were considered to indicate statistical significance.

**Results**

**1. Patients**

Fourteen patients were alive at the time of analysis, with a median age of 14.3 years (range, 1.1–25.2 years). All 15 patients had an identical and homozygous mutation in the CYBA gene: c.7C>T in CYBA exon 1, and p.Q3X in p22phox. The mean follow-up duration per patient was 8.4 years (range, 0.2–12.0 years).

Seven patients (47%) belonged to five families with multiple affected siblings, including four pairs of male-and-female siblings and one pair of female siblings. Three patients among these five families had died before the observation period.
2. Clinical manifestations

The diagnosis of CGD was made at a median age of 2.4 years (range, 0.1–13.1 years); in 7 of the 15 patients (47%) the diagnosis was made before the age of 1 year, and 5 patients (33%) were diagnosed before the age of 5. Only three patients were diagnosed over the age of 5 years (5.1, 7.2, and 13.0 years, respectively). The median age at the onset of severe infection was 0.3 years (range, 0–14.2 years). Thirteen patients (87%) with CGD experienced their first severe infection within the first year of life (Fig. 1).

At diagnosis, the majority of patients 47% (7/15) presented with lymphadenitis. Pneumonia was observed in 33% (5/15) of patients, and perianal abscess, gastrointestinal infection, and fever of unknown origin were noted for 7% (1/15) of patients. The most frequent types of first severe infection were similar to those at the time of diagnosis: lymphadenitis in 47% (7/15), perianal abscess (20%), pneumonia (20%), and fever of unknown origin (13%).

3. Localization of severe infections

The total number of severe infections recorded was 171, and the total period of observation was 126.1 patient-years. The overall incidence of severe infection was 1.36 infections per patient-year. Pneumonia was the most common severe infection, occurring in 32% of patients. Suppurative lymphadenitis was the second most frequent infection, occurring in 29% of the patients. Skin and subcutaneous abscesses were also reported in a considerable number of patients (16%). Other infections reported during follow-up are shown in Table 1.

![Fig. 1. Probability of first severe infection. A severe infection was defined as an episode of infection requiring hospitalization and intravenous antimicrobials or surgical treatment. Thirteen patients (87%) with chronic granulomatous disease experienced their first severe infection within the first year of life.](image)

| Localization                      | Frequency (isolation/severe infection) | Infectious agent                        | No. of isolates |
|-----------------------------------|----------------------------------------|-----------------------------------------|-----------------|
| Pneumonia                         | 9/55                                   | Aspergillus spp.                        | 3               |
|                                   |                                        | Streptococcus pneumoniae               | 1               |
|                                   |                                        | Candida spp.                           | 1               |
|                                   |                                        | Pseudomonas spp.                       | 1               |
|                                   |                                        | Klebsiella pneumoniae                  | 1               |
|                                   |                                        | Mycoplasma pneumonia*                  | 2               |
| Suppurative lymphadenitis         | 2/49                                   | Atypical Mycobacteria                  | 1               |
|                                   |                                        | Staphylococcus aureus                  | 1               |
| Skin and subcutaneous abscess    | 1/28                                   | Serratia marcescens                    | 1               |
| Enterocolitis                     | 3/10                                   | Salmonella spp.                        | 2               |
|                                   |                                        | Enterobacter cloacae                   | 1               |
| Osteomyelitis                     | 0/8                                    | Not identified                         |                 |
| Septicemia                        | 2/5                                    | Candida spp.                           | 1               |
|                                   |                                        | Staphylococcus aureus                  | 1               |
| Fever of unknown origin           | 0/4                                    | Not identified                         |                 |
| Liver abscess                     | 1/4                                    | Serratia marcescens                    | 1               |
| Splenic abscess                   | 0/3                                    | Not identified                         |                 |
| Otitis media with effusion        | 1/2                                    | Burkholderia cepacia                   | 1               |
| Intra-abdominal abscess           | 0/2                                    | Not identified                         |                 |
| Brain abscess                     | 0/1                                    | Not identified                         |                 |
| Total                             | 19/171                                 |                                         | 19              |

*Diagnosed by a mycoplasma antibody titer>1:320.
4. Infectious agents of severe infections

Infectious agents were isolated in 19 of the 171 infections (11.1%) listed in Table 1. In most cases, no infectious agents were detected using proper procedures. *Aspergillus* species was the most frequently isolated microorganism, found in 15.8% of the isolates (3/19), resulting in pneumonia. *Candida* species were responsible for pneumonia and septicemia with a positive blood culture (each one case). *Staphylococcus aureus* was isolated in suppurative lymphadenitis and septicemia with a positive blood culture (each one case). Other microorganisms were gram-negative, such as *Pseudomonas* species, *Klebsiella pneumoniae*, *Salmonella* species, *Serratia marcescens*, *Enterobacter cloacae*, and *Burkholderia cepacia*. Unusual pathogens, such as atypical *Mycobacteria*, were isolated from one case of suppurative BCGitis. Among the pneumonia cases, *Mycoplasma pneumoniae* were identified in two cases, detected by mycoplasma antibody titer.

5. Chronic conditions

Patients with CGD may have various chronic conditions, resulting from chronic inflammation or recurrent infections. The most common condition was hepatosplenomegaly, which was present in all patients. Being underweight and short stature occurred in 93% and 53% of the patients, respectively. Anemia of chronic disease and elevated liver enzymes were seen in 80% and 53% of the patients, respectively, probably resulting from chronic inflammation or recurrent infections.

6. Survival rate

One of the 15 patients with CGD died during the observation period, at the age of 2 years. He died of cardiopulmonary failure as a consequence of recurrent pneumonia caused by *Aspergillus* species. The survival rate for all patients was 93% after 2 years of age, and there was a prolonged survival plateau beyond this time (Fig. 2). Three patients who were alive at the time of analysis were excluded from this study due to lack of sufficient follow-up data.

7. Efficacy of IFN-γ prophylaxis

Seven patients received IFN-γ as prophylactic treatment, and eight patients did not receive IFN-γ prophylaxis for a variety of reasons, including the risk of systemic side-effects, non-compliance due to young age or inconvenience, and the burden of having to receive treatment for life; these latter patients were excluded from our study.

The overall observation periods were 36 and 77.9 patient-years for patients treated with and without IFN-γ, respectively. There were 35 severe infections in the group receiving prophylaxis with IFN-γ, compared with 117 in the group without prophylaxis, and no significant difference in the infection incidence per patient-year between the two groups (P=0.224) was observed (Table 2). The efficacy of IFN-γ prophylaxis was also evaluated by comparing the incidence of severe infections before and after starting continuous prophylaxis with IFN-γ. The observation periods were 12.2 and 36 patient-years for patients treated before, and after, IFN-γ prophylaxis, respectively. There was no significant difference in the infection incidence per patient-year between before and after IFN-γ prophylaxis (P=0.118) (Table 3). To detect the potential effects of IFN-γ in reducing certain types of infection, we analyzed the incidence of each severe infection in both groups of patients before and after IFN-γ prophylaxis. No significant differences in the reductions in certain types of

---

**Table 2. Effectiveness of IFN-γ prophylaxis**

| Variable                        | IFN-γ prophylaxis (-) (n=8) | IFN-γ prophylaxis (+) (n=7) | P value |
|---------------------------------|-----------------------------|-----------------------------|---------|
| Patient-years                   | 77.9                        | 36                          | -       |
| Incidence of severe infections  | 117                         | 35                          | -       |
| Incidence of severe infection per patient-year, median (range) | 1.167 (0.59–3.53) | 1.494 (0.08–35.0) | 0.224* |

IFN, interferon.
*Mann-Whitney U* test.
Table 3. Comparision of before and after starting prophylaxis with IFN-γ

| Variable                                      | IFN-γ prophylaxis | P value |
|-----------------------------------------------|-------------------|---------|
| Patient-years                                 | 12.2              | 36      | -       |
| Incidence of severe infections                | 19                | 35      | -       |
| Incidence of severe infection per patient-year, median (range) | 1.583 (0.00–10.00) | 0.938 (0.59–3.13) | 0.118* |

IFN, interferon. *Wilcoxon signed-rank test.

Discussion

All patients with CGD on Jeju Island were presumed to be the A22γ phenotype. Therefore, we hypothesized that the prognosis of p22γ−/−-deficient patients with CGD on Jeju Island would not be better than that of those with gp91phox−/−-deficient CGD. Except for countries with high rates of consanguineous marriage, the proportion of p22γ−/−-deficient CGD is smaller than other subtypes of CGD. Few reports have described the clinical presentation of p22γ−/−-deficient CGD. In a cohort in Israel, which contained a relatively large number of patients with p22γ−/−-deficient CGD (about 30%), similar to our cohort, most patients with gp91phox−/−- and p22γ−/−-deficient CGD were diagnosed earlier and had a shorter mean survival duration than patients with the other form of CGD. In our cohort, 87% of patients with CGD had their first manifestation within the first year of life. Similarly, 86% of gp91phox−/−-deficient CGD patients in a Korean study had manifestations within the first year of life. Furthermore, the incidence of serious infection per patient (11.4 in our cohort) was similar to that (10.3 in the Korean study) of gp91phox−/−-deficient CGD. Previously reported data regarding the age at diagnosis and first infection, localization of infection, and infectious agents in X-linked CGD followed a similar trend to our cohort.

Since the first description of CGD nearly 60 years ago, the survival rate of patients with CGD has improved. This change may be attributed to better and earlier diagnosis of the disease, development of more effective antimicrobials, prophylaxis with antibiotics, antifungal drugs and IFN-γ, and bone marrow transplantation. The overall survival rate of CGD is now thought to be about 90%. Although a wide range of clinical variability in patients with CGD remains, X-linked CGD generally has an earlier and more severe clinical presentation, and a lower survival rate than the AR subtype. The prognosis of most patients with p22γ−/− subtypes is typically poor, while it is better for those with p47γ−/−-deficient CGD. The prognosis may depend on the affected component of the NADPH oxidase complex, and the effect of the specific mutation on its residual activity.

However, patients with CGD on Jeju Island had a significantly higher survival rate compared with patients with gp91phox−/−-deficient CGD in other studies (93% vs. <50% at 30 years of age). In the Israeli cohort, patients with X-linked CGD had a shorter mean survival time than p22γ−/−-deficient CGD patients, as seen in our cohort. Although these data should be interpreted with caution because of the small CGD subtype sample size, it appears that the specific NADPH oxidase gene mutation may not be linked to survival rates in patients with CGD. A recent study suggested that residual ROI production is more predictive of survival than the specific gene mutation in NADPH oxidase. Even residual ROI production resulted in a significant gain in survival, and ROI production was not correlated with the expression of NADPH oxidase. Interestingly, mutations in the flavin adenine dinucleotide- and NADPH-binding domains of gp91phox may allow normal protein expression, but little residual ROI production, and the amount of ROI production in patients with p22γ−/−-deficient CGD, even with the A22γ phenotype, varied widely. Although residual ROI production may be an important parameter affecting the clinical course and survival, the variability in ROI production and the variable survival rate in patients with the same mutation cannot be explained at present. Further studies are needed to clarify whether residual ROI production can predict survival rates and to ascertain why ROI production does not correlate with NADPH oxidase expression.

The overall incidence of severe infections was 1.36 per patient-year in our cohort. This result is comparable with another retrospective study in Israel, in which the annual infection incidence of p22γ−/−-deficient CGD was 2.4 infections per patient-year before diagnosis and decreased to 0.7 infections per patient-year after diagnosis. All patients in the Israeli cohort received permanent prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) and cefalothin or amoxicillin-clavulanic acid. The decreased rate of infections was likely due to the fact that antibiotic prophylaxis significantly reduced the incidence of bacterial infection in CGD. In addition, until recently, fungal infections were the leading cause of mortality in CGD, and several studies supported the efficacy of antifungal drugs against potential fungal infections in CGD. In our cohort, most patients received prophylactic treatment with TMP-SMX and itraconazole from the point of clinical suspicion or...
observation of fungal infection, although prophylactic treatment was not taken by a large percentage of our patients at the time of analysis. Noncompliance might be due to alarm over potential side-effects of prophylactic antibiotics or the burden of taking drugs daily for life-long. Adequate support, such as regular check-ups by a physician, is needed to improve compliance with prophylactic treatment.

IFN-γ was shown to reduce the number and severity of infections in CGD patients in a large, multinational, multicenter, placebo-controlled study. IFN-γ was effective for all genetic subtypes of CGD. However, in our retrospective study, IFN-γ did not significantly change the rate of severe infections per patient-year or the incidence of infection between before and after IFN-γ treatment. Similar to our study, there was no additional benefit of IFN-γ as prophylactic treatment with cotrimoxazole and itraconazole in a prospective study in Italy. The effectiveness of prophylaxis with IFN-γ is controversial, and the mechanism of how IFN-γ improves the host defense in patients with CGD remains unclear. Further studies with a substantially longer period of observation and significantly more patients under intensive surveillance and monitoring of compliance are necessary to clarify the prophylactic efficacy of IFN-γ.

Our study had several limitations. Because of its retrospective nature, this study could not precisely define the time at which patients suffered from the various infections. Multiple infections are sustained in patients with CGD by different strains of the same few species of bacteria. We were able to detect such recurrences of mild infections in a large number of CGD patients. To compare clinical data among different cohorts of patients with CGD, we adopted severe infection as a measure to evaluate clinical manifestations and the efficacy of IFN-γ prophylaxis. In addition, we could not rule out confounding factors when analyzing the efficacy of IFN-γ prophylaxis, because we excluded the effects of antibiotic and antifungal prophylaxis. As mentioned above, a large number of the patients did not take their prescribed prophylactic treatments at the time of our analysis, further confounding the statistical analysis of the efficacy of IFN-γ prophylaxis.

Although the total number of patients in our cohort was small, and the follow-up duration was relatively short, we demonstrated that patients with p22phox-deficient CGD on Jeju Island showed no obviously different clinical manifestations from X-linked CGD as described in other studies, although they did have a significantly higher survival rate compared with patients with X-linked CGD. Further studies are needed to determine why CGD patients on Jeju Island have a higher survival rate despite their p22phox-deficiency. We suggest that early diagnosis, aggressive management of infections, continued intensive surveillance, and monitoring of compliance of prophylactic treatment will help to reduce the morbidity and mortality rates of patients with CGD.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by a research grant from the Jeju National University Hospital Research Fund of Jeju National University in 2013.

References

1. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
2. Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cell Mol Life Sci 2012;69:7-15.
3. Segal BH, Vey S, Maleh H, Cowan MJ. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011;17(Suppl):S123-31.
4. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am 2013;27:89-99.
5. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol 2008;30:209-35.
6. Roos D, Kuhrs DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010;45:246-65.
7. Roos D, Kuhrs DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, et al. Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update). Blood Cells Mol Dis 2010;44:291-9.
8. Matute JD, Arias AA, Wright NA, Wrobel I, Waterhouse CC, Li XJ, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009;114:3309-15.
9. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One 2009;4:e5234.
10. Rhim JW, Kim KH, Kim DS, Kim BS, Kim JS, Kim CH, et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci 2012;27:788-93.
11. Kim YM, Park JE, Kim JY, Lim HK, Nam JK, Cho M, et al. Genetic analysis of 10 unrelated Korean families with p22-phox-deficient chronic granulomatous disease: an unusually identical mutation of the CYBA gene on Jeju Island, Korea. J Korean Med Sci 2009; 24:1045-50.
12. Cho M, Shin KS. Chronic granulomatous disease on Jeju Island, Korea. J Genet Med 2013;10:1-6.
13. Wolach B, Gavrieli R, de Boer M, Gottesman G, Ben-Ari J, Rottem M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol 2008;129:103-14.
14. Teimourian S, Zomorodian E, Badalzadeh M, Pouya A, Kan-
nengiesser C, Mansouri D, et al. Characterization of six novel mutations in CYBA: the gene causing autosomal recessive chronic granulomatous disease. Br J Haematol 2008;141:848–51.

15. Kim JG, Shin KS, Park JS. Clinical study on chronic granulomatous disease in Korea. Korean J Immunol 1999;21:271-83.

16. Liese J, Kloos S, Jendrossek V, Petropoulou T, Wintergerst U, Notheis G, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000;137:687–93.

17. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008;126:155-64.

18. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010;363:2600-10.

19. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509–16.

20. Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA, Darnell D, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39:692-9.

21. Guide SV, Stock F, Gill VJ, Anderson VL, Malech HL, Gallin JJ, et al. Reinfection, rather than persistent infection, in patients with chronic granulomatous disease. J Infect Dis 2003;187:845-53.